Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma.
Blood
; 143(7): 597-603, 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38048552
3.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
4.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37506339
5.
Quantification of cyclin D1 and D2 proteins in multiple myeloma identifies different expression patterns from those revealed by gene expression profiling.
Haematologica
; 109(3): 877-887, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646661
6.
Endothelial Activation and Stress Index in adults undergoing allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide-based prophylaxis.
Cytotherapy
; 26(1): 73-80, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952139
7.
Impact of letermovir prophylaxis in CMV reactivation and disease after allogenic hematopoietic cell transplantation: a real-world, observational study.
Ann Hematol
; 103(2): 609-621, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37957371
8.
Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study.
Lancet Oncol
; 24(8): 913-924, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414060
9.
Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.
Br J Haematol
; 200(2): 187-196, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36210485
10.
Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma.
Blood
; 137(1): 49-60, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32693406
11.
Clinical perspectives on the optimal use of lenalidomide plus bortezomib and dexamethasone for the treatment of newly diagnosed multiple myeloma.
Haematologica
; 108(11): 2894-2912, 2023 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37608773
12.
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients.
Haematologica
; 108(10): 2753-2763, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37102598
13.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-38031761
14.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37132225
15.
Real-world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45-year period.
Br J Haematol
; 196(3): 649-659, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34622447
16.
Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
Br J Haematol
; 198(6): 988-993, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35608261
17.
Teclistamab, a B-cell maturation antigenâ×âCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
Lancet
; 398(10301): 665-674, 2021 08 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-34388396
18.
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma.
Blood
; 135(26): 2375-2387, 2020 06 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-32299093
19.
Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma.
Blood
; 136(2): 199-209, 2020 07 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32325491
20.
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.
Hematol Oncol
; 40(5): 1020-1029, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-35653225